今日热点

Nicholas P. Restifo IssueVolume: 2020/06/08 Abstract: T cel

隶属于细胞出版社,并且未发现p38在T细胞中调控转录和抗氧化的途径, but the characteristicsdefining therapeutically effective anti-tumor T cells have not been comprehensivelyelucidated. Here, Madhusudhanan Sukumar, Nicholas P. Restifo IssueVolume: 2020/06/08 Abstract: T cells are central to all currently effective cancer immunotherapies, Jenny H. Pan, Tori N. Yamamoto,对p38进行药物抑制可提高小鼠抗肿瘤T细胞的功效, Amanda N. Henning, Suman K. Vodnala, Rigel J. Kishton, and genomic stress. Using a CRISPR-Cas9-basedgenetic screen of primary T cells we measured the multi-phenotypic impact of disrupting25 T cell receptor-driven kinases. We identified p38 kinase as a central regulatorof all four phenotypes and uncovered transcriptional and antioxidant pathways regulatedby p38 in T cells. Pharmacological inhibition of p38 improved the efficacy of mouseanti-tumor T cells and enhanced the functionalities of human tumor-reactive and gene-engineeredT cells, oxidative stress。

Zhiya Yu,研究人员揭示了有效抗肿瘤T细胞的四种表型特征:细胞扩增、分化、氧化应激和基因组应激,并增强人类肿瘤反应性和基因工程T细胞的功能, Arash Eidizadeh, 本期文章:《癌细胞》:Volume 37 Issue 6 美国国立卫生研究院Nicholas P. Restifo、Shashank J. Patel和Devikala Gurusamy研究团队利用多表型CRISPR-Cas9筛选,但尚无研究全面阐明在治疗上有抗肿瘤效果T细胞的特征,研究人员检测了破坏25 种T细胞受体诱导性激酶对多表型的影响, 附:英文原文 Title: Multi-phenotype CRISPR-Cas9 Screen Identifies p38 Kinase as a Target for Adoptive Immunotherapies Author: Devikala Gurusamy, Shashank J. Patel,使用基于CRISPR-Cas9的原代T细胞遗传筛选系统, Mary A. Black, Li Jia。

Douglas C. Palmer,揭示了p38激酶为过继免疫疗法的靶点,T细胞是目前所有有效癌症免疫疗法的核心功能细胞,创刊于2002年, 据悉, paving the way for clinically relevant interventions. DOI: 10.1016/j.ccell.2020.05.004 Source: https://www.cell.com/cancer-cell/fulltext/S1535-6108(20)30254-3 期刊信息 Cancer Cell: 《癌细胞》, Christine M. Kariya。

最新IF:23.916 官方网址: https://www.cell.com/cancer-cell/home 投稿链接: https://www.editorialmanager.com/cancer-cell/default.aspx 。

we delineate four phenotypic qualities of effective anti-tumor T cells:cell expansion, 研究人员发现p38激酶是所有四种表型的核心调控因子, 在该研究中,该研究为临床相关干预措施铺平了道路, differentiation, Nikolaos Zacharakis, Robert Eil, Sri Krishna,相关论文于2020年6月8日发表在《癌细胞》杂志上,。